Oklahoma Medical Research Foundation | Oklahoma City, OK

Research site

(Unclaimed)

Location

825 N.E. 13th Street, Oklahoma City, Oklahoma, United States of America

Site insights

Top conditions

Top treatments

Ocrelizumab

Interferon

Baricitinib

fluorouracil

Gemcitabine

Fluorouracil

cyclophosphamide

paclitaxel

Tofacitinib

Methotrexate

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

12 of 122 total trials

A Rollover Study to Evaluate the Long-Term Safety and Efficacy of Ocrelizumab In Patients With Multiple Sclerosis (OLERO)

This is a Phase IIIb, single-arm, multicenter, OLE study. Participants receiving ocrelizumab as an investigational medicinal product (IMP) in a Roche...

Active, not recruiting

Multiple Sclerosis

Drug: Ocrelizumab

A Study Evaluating the Efficacy and Safety of Afimetoran Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (SLE)

The purpose of this study is to evaluate the effectiveness, safety and tolerability of Afimetoran in participants with active Systemic Lupus Erythema...

Enrolling

Systemic Lupus Erythematosus

Other: Placebo

Drug: Afimetoran

Locations recently updated

A Study of Baricitinib (LY3009104) in Participants With Rheumatoid Arthritis (RA-BRIDGE)

This post-marketing study is designed to compare the safety of baricitinib versus tumor necrosis factor (TNF) inhibitors with respect to venous throm...

Active, not recruiting

Rheumatoid Arthritis

Drug: Baricitinib

Drug: TNF Inhibitor

A Study of Zetomipzomib (KZR-616) in Patients With Active Lupus Nephritis (PALIZADE)

The purpose of this study is to assess the efficacy and safety of zetomipzomib (30 mg or 60 mg) compared with placebo in achieving renal response aft...

Enrolling

Lupus Nephritis

Drug: placebo

Drug: zetomipzomib

A Study to Evaluate Effectiveness and Safety of Deucravacitinib (BMS-986165) Compared With Placebo in Participants With Active Systemic Lupus Erythematosus (POETYK SLE-2)

The purpose of this study is to evaluate the effectiveness and safety of deucravacitinib compared with placebo in an active moderate to severe System...

Enrolling

Systemic Lupus Erythematosus

Drug: Deucravacitinib

Other: Placebo

A Study To Evaluate The Efficacy And Safety Of Obinutuzumab In Patients With ISN/RPS 2003 Class III Or IV Lupus Nephritis (REGENCY)

This study will evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab compared with placebo in patients with International Society of N...

Active, not recruiting

Lupus Nephritis

Drug: Placebo

Drug: MMF

Cladribine Tablets: Collaborative Study to Evaluate Impact On Central Nervous System Biomarkers in Multiple Sclerosis (CLOCK-MS)

The purpose of this study is to better understand the mechanism of action (MoA) of cladribine tablets by exploring the effect on central nervous syst...

Active, not recruiting

Multiple Sclerosis

Multiple Sclerosis, Relapsing-Remitting

Drug: Cladribine

Efficacy and Safety Studies of Frexalimab (SAR441344) in Adults With Relapsing Forms of Multiple Sclerosis (FREXALT)

The purpose of each study is to independently measure the annualized relapse rate (ARR) with administration of frexalimab compared to a daily oral do...

Enrolling

Multiple Sclerosis

Drug: Activated charcoal

Drug: Cholestyramine

Efficacy and Safety Study of Frexalimab (SAR441344) in Adults With Nonrelapsing Secondary Progressive Multiple Sclerosis (FREVIVA)

The purpose of this randomized, double-blind, placebo-controlled, parallel group study is to determine the efficacy of frexalimab in delaying the dis...

Enrolling

Multiple Sclerosis

Drug: Frexalimab

Drug: Placebo

Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE (NAIVE)

This study to examines the impact of anifrolumab on disease activity, immune phenotypes, and development of neutralizing antibodies to quadrivalent i...

Enrolling

Systemic Lupus Erythematosus (SLE)

Drug: Standard of Care

Drug: Anifrolumab

Ocrelizumab Discontinuation in Relapsing Multiple Sclerosis (AMS05)

This study is a prospective, multi-center, randomized, double blinded, placebo-controlled study of OCR treatment-discontinuation in patients with ear...

Enrolling

Multiple Sclerosis

Drug: Ocrelizumab

Drug: Placebo for Ocrelizumab

Relapsing Forms of Multiple Sclerosis (RMS) Study of Bruton's Tyrosine Kinase (BTK) Inhibitor Tolebrutinib (SAR442168) (GEMINI 1)

Primary Objective:To assess efficacy of daily SAR442168 compared to a daily dose of 14 mg teriflunomide (Aubagio) measured by annualized adjudicated...

Active, not recruiting

Relapsing Multiple Sclerosis

Drug: Placebo to match Teriflunomide

Drug: Placebo to match Tolebrutinib